FINWIRES · TerminalLIVE
FINWIRES

HKG:3759

8 stories mentioning HKG:3759Updated 6d ago

Every FINWIRES story that references HKG:3759, newest first.

Asia

Pharmaron Beijing Sells 2.18 Billion Yuan Convertible Bonds

Pharmaron Beijing (HKG:3759, SHE:300759) completed the issue of 2.18 billion yuan of USD-settled zero-coupon convertible bonds maturing in 2027 to raise net proceeds of $327.2 million.The bonds are convertible into Hong Kong-listed Shares at HK$36.08 apiece, according to a Wednesday Hong Kong bourse filing.The company will use proceeds for business expansion, development of its lab and CDMO services, refinancing of debt, general corporate purposes, and working capital.

HKG:3759SHE:300759
Asia

Pharmaron Beijing to Raise $327 Million Via Zero-Coupon Convertible Bonds

Pharmaron Beijing (HKG:3759, SHE:300759) plans to issue 2.18 billion yuan of USD-settled zero-coupon convertible bonds due in 2027, according to a Thursday Hong Kong bourse filing.The company expects to secure net proceeds of about $327.2 million, with 70% earmarked for business expansion and the remainder to refinance existing debt, and for general corporate purposes and working capital.The bonds will carry an initial conversion price of HK$36.08 per H-share, representing a 16.76% premium to the Aug. 26 closing price.If fully converted, they would result in the issuance of about 70.5 million new H-shares.The bonds are expected to mature on or around Aug. 31, 2027, with the subscription scheduled to close on Sept. 2, subject to conditions.

HKG:3759SHE:300759
Asia

Pharmaron Beijing's Profit Rises 7% in H1

Pharmaron Beijing (HKG:3759, SHE:300759) posted an attributable net profit of 750.2 million yuan for the first half of 2026, up 7% from 701.4 million yuan a year earlier.Earnings per share stood at 0.4113 yuan, compared with 0.3978 yuan in the year-ago period, according to a Thursday Hong Kong bourse filing.Revenue increased 18% year over year to 7.60 billion yuan from 6.44 billion yuan.

HKG:3759SHE:300759
Asia

Nomura Adjusts Pharmaron Beijing's Price Target to HK$32.20 From HK$27.33, Keeps at Buy

Pharmaron Beijing (HKG:3759) has an average rating of buy and mean price target of HK$29.89, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

HKG:3759
Asia

Hong Kong Stocks Advance on Robust China Trade Data; Pharmaron, CNGR Jump on Profit Outlook

Hong Kong stocks closed higher Tuesday as stronger-than-expected Chinese trade data offset renewed concerns over escalating U.S.-Iran tensions and higher oil prices.The Hang Seng Index rose 0.5%, or 127.01 points, to close at 24,340.73, while the Hang Seng China Enterprises Index gained 0.5%, or 37.11 points, to finish at 8,103.08.China's June trade data exceeded expectations, pointing to resilient external demand. Exports rose 27% year over year, while imports climbed 36%, with both figures topping analysts' forecasts.The trade surplus widened to $125.6 billion from $105.4 billion in May, beating the consensus forecast.Meanwhile, oil prices climbed after U.S. President Donald Trump said Washington was reinstating its blockade of Iranian shipping and would impose a 20% fee on cargo transiting the Strait of Hormuz.In corporate news, Pharmaron Beijing (HKG:3759, SHE:300759) closed over 6% higher after forecasting up to a 10% rise in first-half profit.CNGR Advanced Material (HKG:2579, SHE:300919) advanced over 8% after flagging an 84% first-half profit jump.

Hang SengHKG:2579HKG:3759SHE:300759SHE:300919
Asia

Pharmaron Forecasts Profit to Rise Up to 10% in H1

Pharmaron Beijing (HKG:3759, SHE:300759) expects attributable net profit of 729.5 million yuan to 771.5 million yuan for the six months ended June 30, up 4% to 10% from 701.4 million yuan a year earlier, according to a Monday filing with the Hong Kong bourse.The pharmaceutical company expects first-half revenue of 7.47 billion yuan to 7.66 billion yuan, up 16% to 19% from 6.44 billion yuan in the prior-year period.Pharmaron attributed the expected growth to stronger strategic customer demand and robust growth in its small-molecule CDMO business, with newly signed orders rising more than 30% in the first half.

HKG:3759SHE:300759
Asia

Pharmaron Plans 5 Billion Yuan Investments in Drug Manufacturing Projects; Shares Slip 3%

Pharmaron Beijing (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.

HKG:3759SHE:300759
Asia

Pharmaron Beijing's Q1 Profit Climbs 9.8%

Pharmaron Beijing (HKG:3759, SHE:300759) recorded a 9.8% rise in attributable profit in the first quarter of 2026 to 335.4 million yuan from 305.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.The pharmaceutical company's earnings per share rose to 0.185 yuan from 0.1733 yuan in the corresponding period of the previous fiscal year.Revenue jumped 15% to 3.58 billion yuan from 3.1 billion yuan in the year-ago period.

HKG:3759SHE:300759

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:3759 in your portfolio
WheelAI
WheelAI
Analyze HKG:3759 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:3759